Subscribe To
ANGN / Angion (ANGN) Down on Merger Agreement With Private Biotech
ANGN News
By Zacks Investment Research
January 18, 2023
Angion (ANGN) Down on Merger Agreement With Private Biotech
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-0 more_horizontal
By Benzinga
June 30, 2022
Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinu more_horizontal
By Zacks Investment Research
December 13, 2021
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint. more_horizontal
By Zacks Investment Research
December 13, 2021
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint. more_horizontal
By Zacks Investment Research
December 13, 2021
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint. more_horizontal